Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.01 - $34.47
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.59M
Market Cap
$3.12B
Enterprise Value$3.26B
Total Cash (Recent Filing)$374.69M
Total Debt (Recent Filing)$23.00K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
May 28, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.62
Shares Outstanding169,860,690
10 Day Avg. Volume2,641,098
30 Day Avg. Volume1,592,205
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.13K
Enterprise Value/Ebitda-8.06
Forecast
1Y Price Target
$47.50Price Target Upside158.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyBatoclimab drives impressive absolute clinical responses at a 680mg dose, comparable to other therapies at a 340mg dose.
Market PositioningThe ability to achieve greater IgG reductions versus first-generation agents offers potential for a differentiated profile and first-in-class positioning within key markets.
Bears Say
Data ReportingSome pushback has been received regarding the lack of time course data, making comparisons with other trials challenging.
Price ObjectiveThe price objective for Immunovant, Inc. was lowered due to reduced peak sales expectations for the company's FcRn program in the MG indication.
---
Ownership Overview
2.73% Insiders
15.46% Mutual Funds
24.73% Other Institutional Investors
49.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $17.01 and its highest was $34.47 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $3.12B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is May 28, 2025 which is in 58 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 06, 2025. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.752 by -$0.008.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.71.
How many shares outstanding does Immunovant have?
Immunovant has 169,860,690 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.752. Following the earnings report the stock price went down -9.551%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
---
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.50 (158.57% Upside)
$47.50 (158.57% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $335.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.14%
12-Months-Change
Fundamentals
Return on Equity
-74.17%
Trailing 12-Months
Asset Growth
-40.83%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
---
IMVT Stock 12 Month Forecast
Average Price Target
$47.50
▲(158.57% Upside)
Technical Analysis
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+73.79%
reiterated a buy rating 11 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +73.79% per trade.
---